Related Experiment Video

Updated: Jul 17, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer

Shuping Yin1, Han Cui1, Shuang Qin2

  • 1Department of Obstetrics and Gynecology, Changxing People's Hospital of Zhejiang Huzhou, Changxing 313100, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|August 30, 2023
PubMed

Insights

Transforming growth factor-beta (TGF-β) is a key molecule in advanced cervical cancer, promoting tumor growth and immune evasion. Blocking TGF-β shows promise for improving cancer therapies, including immunotherapy.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunotherapy

Background:

  • Cervical cancer poses a significant global health risk to women.
  • Identifying molecular targets is crucial for developing effective cervical cancer treatments.
  • Transforming growth factor-beta (TGF-β) has emerged as a potential therapeutic target.

Purpose of the Study:

  • To highlight the role of TGF-β in advanced cervical cancer progression.
  • To discuss the potential of TGF-β blockade in enhancing cancer therapies.
  • To explore novel therapeutic strategies targeting TGF-β and immune checkpoints.

Main Methods:

  • Review of current scientific literature on TGF-β in cervical cancer.
  • Analysis of TGF-β's involvement in metastasis, stemness, drug resistance, and immune evasion.
  • Examination of clinical studies involving TGF-β inhibitors and immune checkpoint agents.

Main Results:

  • TGF-β actively promotes tumor development in advanced cervical cancer.
  • TGF-β blockade demonstrates efficacy in improving therapeutic outcomes, particularly with immunotherapy.
  • Bispecific antibodies targeting TGF-β and PD-L1 are under clinical investigation.

Conclusions:

  • TGF-β is a critical mediator of cervical cancer progression and therapeutic resistance.
  • Targeting TGF-β offers a promising strategy to enhance the effectiveness of existing cancer treatments.
  • Future cervical cancer therapies may involve bispecific antibodies for combined TGF-β and immune checkpoint inhibition.
Keywords:
Bispecific antibodyCervical cancerImmunotherapyPD-L1TGF-β

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

416
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro10:36

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Published on: January 9, 2018

7.2K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K